

Supplementary Materials

Three-dimensional analysis of the interactions between *h*LDH5 and its inhibitors

Giulio Poli, Carlotta Granchi, Mohamed Aissaoui, Filippo Minutolo, Tiziano Tuccinardi
E-mail: tiziano.tuccinardi@unipi.it

Table of Contents

Figure S1. Superimposed structures of <i>h</i> LDH5 showing the large and small domains	S2
Figure S2. Chemical structure of oxamate (1) and H-bond interactions	S3
Figure S3. Chemical structure of 3 and X-ray structure of <i>h</i> LDH5 in complex with compound 3	S4
Figure S4. Chemical structure of 7 and X-ray structure of <i>h</i> LDH5 in complex with compound 7	S5
Figure S5. Chemical structure of 8 and X-ray structure of <i>h</i> LDH5 in complex with compound 8	S5
Figure S6. Chemical structure of 9 and X-ray structure of <i>h</i> LDH5 in complex with compound 9	S6
Figure S7. Chemical structure of 10 and X-ray structure of <i>h</i> LDH5 in complex with compound 10	S6
Figure S8. Chemical structure of 11 and X-ray structure of <i>h</i> LDH5 in complex with compound 11	S7
Figure S9. Chemical structure of 12 and X-ray structures of <i>h</i> LDH5 in complex with compound 12	S8
Figure S10. Chemical structure of 14 , 15 and X-ray structures of <i>h</i> LDH5 in complex with 14 and 15	S9
Figure S11. Schematic 2D representation of the 18 - <i>h</i> LDH5 and 19 - <i>h</i> LDH5 H-bond interactions	S10
Figure S12. Schematic 2D representation of the 20 - <i>h</i> LDH5 H-bond interactions	S10




Figure S1. Superimposed structures of *h*LDH5 showing the large (green) and small (red) domains (PDB code 1I10). The active-site loop in the open (sky-blue) and closed (dark slate gray) conformation is highlighted. NADH and oxamate (**1**) are shown in purple and yellow, respectively.




Figure S2. Chemical structure of oxamate (**1**) and H-bond interactions with *h*LDH-A identified in close proximity to the nicotinamide fragment of NADH, **1** and the residues delimiting the SBP and NBP (A), or between NADH and the residues delimiting the ABP (B) (PDB code 1I10). NADH and **1** are shown in purple and yellow, respectively.




Figure S3. Chemical structure of **3** and X-ray structure of *h*LDH5 in complex with compound **3** (PDB code 4I9H). The active site residues interacting with the inhibitor are shown and the ligand-protein H-bonds are highlighted.





Figure S4. Chemical structure of **7** and X-ray structure of hLDH5 in complex with compound **7** (PDB code 4QO8). The active site residues interacting with the inhibitor are shown and the ligand-protein H-bonds are highlighted.





Figure S5. Chemical structure of **8** and X-ray structure of hLDH5 in complex with compound **8** (PDB code 4R69). The active site residues interacting with the inhibitor are shown and the ligand-protein H-bonds are highlighted.




Figure S6. Chemical structure of **9** and X-ray structure of hLDH5 in complex with compound **9** (PDB code 4R68). The active site residues interacting with the inhibitor are shown and the ligand-protein H-bonds are highlighted




Figure S7. Chemical structure of **10** and X-ray structure of hLDH5 in complex with compound **10** (PDB code 4RLS). The active site residues interacting with the inhibitor are shown and the ligand-protein H-bonds are highlighted.




Figure S8. Chemical structure of **11** and X-ray structure of hLDH5 in complex with compound **11** (PDB code 5IXS). The active site residues interacting with the inhibitor are shown and the ligand-protein H-bonds are highlighted




Figure S9. Chemical structure of **12** and (A) X-ray structures of *h*LDH5 in complex with compound *R*-**12** (PDB code 4ZVV); (B) X-ray structures of *h*LDH5 in complex with compound *S*-**12** (PDB code 5IXY). The active site residues interacting with the inhibitors are shown and the ligand-protein H-bonds are highlighted.






Figure S10. Chemical structure of **14** and **15** and (A) X-ray structures of *h*LDH5 in complex with compound **14** (PDB code 4QT0) and (B) compound **15** (PDB code 4QSM). The active site residues interacting with the inhibitors are shown and the ligand-protein H-bonds are highlighted.




Figure S11. Schematic 2D representation of the **18**-LDH5 (1) and **19**-LDH5 (2) H-bond interactions.




Figure S12. Schematic 2D representation of the **20**-LDH5 H-bond interactions.